Anteris Challenges TAVR Industry to Rethink Long-Term Valve Performance

For over two decades, TAVR has served as a breakthrough for high-risk patients, prioritizing procedural access and speed. However, Anteris Technologies argues that this legacy approach often ignores the necessity of restoring natural blood flow. When treating patients in their 60s, the goal of a single successful procedure is no longer sufficient if the implant fails to provide lasting, high-quality cardiac function.

"The standard must move from 'was the implant successful?' to 'did we achieve disease modification or make it worse?'" said Wayne Paterson, CEO of Anteris. The company contends that current valve designs often leave patients in a state of mild residual disease. To address this, they have developed the DurAVR THV, an investigational biomimetic valve designed to mimic the anatomy of a healthy human aortic valve, promoting natural laminar blood flow rather than just mechanical opening and closing.

This debate is fueling a shift toward "choosing the first valve wisely." Because failed transcatheter valves can complicate future interventions—often precluding open-heart surgery—the initial choice is now a critical long-term commitment. Anteris is currently testing its device against existing market options in the randomized PARADIGM trial, seeking to provide the direct clinical evidence needed to prove that valve design directly correlates with improved long-term patient outcomes.